Expression Of17β-HSD1in Breast Cancer And Its Relationship With Prognosis

17β-HSD1is an enzyme that has the function of reduction, it plays animportant role in the process of synthesis in the metabolism of estrogen,and it’s the last step of key enzyme that catalytic activity of estrogen (E1)into activity estrogen (E2). The development of breast cancer is closelyassociated with estrogen, so17β-HSD1of mammary gland topicalestrogen levels also plays an important role in the correspondingadjustment. Related studies have shown that17β-HSD1has a dual rolefor the spread of the breast cancer cells, it can make breast cancer cellsproliferation, affect the breast cancer cells cycle, and promote the growthof tumor.By using immunohistochemical method,detection89cases ofbreast cancer patients’ pathologic specimens who surgical operationtreatment in Jilin University First Hospital from2001to2008,studyexpression of17β-HSD1in breast cancer tissue, and the relationship toclinical parameters, it to understand and evaluate the prognosis of patientswith breast cancer and setting individualized treatment provides furtherclues.Objective:Suggestions the expressionof17β-HSD1inbreastcanceranditsrelationshipwithprognosisMethods:Collected89cases of patients who with breast cancer surgery in JilinUniversity Hospital from2001to2008, excluded by a follow-up databasedata deletion in3patients, finally in86cases patient specimens,In casesof patients were all female, age from31to77, the median age was50; thefollow-up time from8to135months,the median time was76months.Thepatients with modified radical mastectomy was75patients,with thebreast-conserving surgery was11patients.All the patients have not madeany treatment before the operation.By using the method ofimmunehistochemical to17β-HSD1,by SPSS19.0software for statisticaldata analysis, using chi-square comparison with the experimentdata,using Kaplan Meier method and the log-rank test in survivalanalysis.All statistics with p<0.05for the difference was statistically significant.Results:17β-HSD1expression in the cell nucleus,there were57cases (66%)with strong positive expression in breast cancer.Using the chi-squareanalysis the expression of17β-HSD1with the patients’ age, menopausal status, tumor size, lymph node metastasis number, ER/PR, HER-2,Ki-67,endocrine therapy and such as transferring situation.The reesults show that17β-HSD1with high expression in the breast cancer patients who less than50years old（p=0.027）,the tumor size less than5cm（p＜0.001） and had no recurrence and metastasis（p=0.028）.The breast cancer patients that at age50or less, premenopause, ER(+), PR(+), and HER-2(-) and stage Ⅲ,17β-HSD1with highexpression is better than17β-HSD1with low expression in theallover survival（p＞0.05）and disease free survival（p＜0.05）.Conclusion:1.17β-HSD1with high expression in the breast cancer patients who lessthan50years old,the tumor size less than5cm and had no recurrence andmetastasis.2.The breast cancer patients that at age50or less, premenopause, ER(+),PR(+), and HER-2(-) and stage Ⅲ, expression of17β-HSD1is one of theprognosis factors affect the DFS.